文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌患者低剂量[18F]PSMA-1007全身动态与静态PET/CT联合显像

Combined whole-body dynamic and static PET/CT with low-dose [18F]PSMA-1007 in prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-01-30

研究纳入38例前列腺癌患者,其中34例接受60分钟全身动态PET/CT后行静态全身PET/CT,4例仅行静态全身PET/CT,示踪剂为2 MBq/kg [18F]PSMA-1007。静态图像按10、8、6、5、4、2分钟重建比较病灶检出率与图像质量;结果显示扫描时间从10分钟缩短至5分钟时病灶检出率无显著差异,结论认为低剂量[18F]PSMA-1007 LAFOV PET/CT可将静态扫描时间减少50%而不显著影响病灶检出率和客观图像质量。

要点

  • 38例前列腺癌患者中34例行动态全身PET/CT(60分钟)后静态显像,4例仅行静态显像,示踪剂为2 MBq/kg [18F]PSMA-1007。
  • 以PET-10检出169个病灶为基准,PET-8检出率100%、PET-6为98.8%、PET-5为95.9%,从10分钟缩短至5分钟病灶检出率无显著差异。
  • 除PET-2外,其他较短采集方案与PET-10的差异对任何患者的临床管理均无影响。

核心结论

  • 在前列腺癌中,低剂量(2 MBq/kg)[18F]PSMA-1007 LAFOV PET/CT可将静态扫描时间减少50%,而不显著影响病灶检出率和客观图像质量。
  • 动态PET可在全身水平阐明[18F]PSMA-1007在肿瘤病灶和正常器官中相关的生理分子通路。

研究设计与样本

  • 共38例前列腺癌患者纳入分析,用于分期或再分期目的。
  • 34例患者接受动态全身PET/CT(60分钟)后行静态全身PET/CT,4例患者仅行静态全身PET/CT。
  • 所用放射性活度为2 MBq/kg [18F]PSMA-1007。
  • 静态PET图像按10分钟(PET-10)重建,并进一步拆分为8分钟(PET-8)、6分钟(PET-6)、5分钟(PET-5)、4分钟(PET-4)和2分钟(PET-2)时长组。
  • 动态PET/CT数据分析基于双组织室模型,使用从降主动脉获得的图像衍生输入函数。

主要发现

  • 病灶检出率分析显示,将PET采集时间从10分钟缩短至5分钟时无显著差异。
  • PET-10共计数169个病灶;较短采集的病灶检出率(肿瘤病灶差异90%分位的95%CI)分别为PET-8 100%(169/169,95%CI:0-0)、PET-6 98.8%(167/169,95%CI:0-1)、PET-5 95.9%(162/169,95%CI:0-3)、PET-4 91.7%(155/169,95%CI:1-2)、PET-2 85.2%(144/169,95%CI:1-6)。
  • 除PET-2外,PET-10与其他较短采集方案之间观察到的差异对任何患者的临床管理均无影响。
  • 客观图像质量评价显示,随采集时间缩短,肿瘤与背景比值(TBR)无显著下降,尽管脾脏信噪比(SNR)逐渐降低。
  • 双组织室模型显示,肿瘤病灶和腮腺中参数k3值显著高于肝脏和脾脏,反映这些组织中示踪剂与PSMA分子的特异性结合及内化率更高,相应的时间-活性曲线亦支持该发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: In addition to significant improvements in sensitivity and image quality, the recent introduction of long axial field-of-view (LAFOV) PET/CT scanners has enabled dynamic whole-body imaging for the first time. We aim herein to determine an appropriate acquisition time range for static low-dose [18F]PSMA-1007 PET imaging and to investigate the whole-body pharmacokinetics of [18F]PSMA-1007 by dynamic PET with the LAFOV Biograph Vision Quadra PET/CT in a group of prostate cancer patients. METHODOLOGY: In total, 38 prostate cancer patients were enrolled in the analysis for staging or re-staging purposes. Thirty-four patients underwent dynamic whole-body PET/CT (60 min) followed by static whole-body PET/CT and four patients underwent static whole-body PET/CT only. The activity applied was 2 MBq/kg [18F]PSMA-1007. The static PET images of 10-min duration (PET-10) were reconstructed and further split into 8-min (PET-8), 6-min (PET-6), 5-min (PET-5), 4-min (PET-4), and 2-min (PET-2) duration groups. Comparisons were made between the different reconstructed scan times in terms of lesion detection rate and image quality based on SUV calculations of tumor lesions and the spleen, which served as background. Analysis of the dynamic PET/CT data was based on a two-tissue compartment model using an image-derived input function obtained from the descending aorta. RESULTS: Analysis of lesion detection rate showed no significant differences when reducing PET acquisitions from 10 up to 5 min. In particular, a total of 169 lesions were counted with PET-10, and the corresponding lesion detection rates (95% CI for the 90% quantile of the differences in tumor lesions) for shorter acquisitions were 100% (169/169) for PET-8 (95% CI: 0-0), 98.8% (167/169) for PET-6 (95% CI: 0-1), 95.9% (162/169) for PET-5 (95% CI: 0-3), 91.7% (155/169) for PET-4 (95% CI: 1-2), and 85.2% (144/169) for PET-2 (95% CI: 1-6). With the exception of PET-2, the differences observed between PET-10 and the other shorter acquisition protocols would have no impact on any patient in terms of clinical management. Objective evaluation of PET/CT image quality showed no significant decrease in tumor-to-background ratio (TBR) with shorter acquisition times, despite a gradual decrease in signal-to-noise ratio (SNR) in the spleen. Whole-body quantitative [18F]PSMA-1007 pharmacokinetic analysis acquired with full dynamic PET scanning was feasible in all patients. Two-tissue compartment modeling revealed significantly higher values for the parameter k3 in tumor lesions and parotid gland compared to liver and spleen, reflecting a higher specific tracer binding to the PSMA molecule and internalization rate in these tissues, a finding also supported by the respective time-activity curves. Furthermore, correlation analysis demonstrated a significantly strong positive correlation (r = 0.72) between SUV and k3 in tumor lesions. CONCLUSIONS: In prostate cancer, low-dose (2 MBq/kg) [18F]PSMA-1007 LAFOV PET/CT can reduce static scan time by 50% without significantly compromising lesion detection rate and objective image quality. In addition, dynamic PET can elucidate molecular pathways related to the physiology of [18F]PSMA-1007 in both tumor lesions and normal organs at the whole-body level. These findings unfold many of the potentials of the new LAFOV PET/CT technology in the field of PSMA-based diagnosis and theranostics of prostate cancer.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sachpekidis C, Pan L, Groezinger M, et al. Combined whole-body dynamic and static PET/CT with low-dose [18F]PSMA-1007 in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2024. PMID: 38286936. doi:10.1007/s00259-024-06620-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。